Volume 15, Number 1—January 2009
Linezolid-Resistant Staphylococcus cohnii, Greece
|Patient no.||Gender/ age, y||Medical history||Reason for hospitalization||Previous treatment||Date of hospital admission||Date of sample collection||Outcome||Date of death or discharge|
|1||F/82||No relevant history||Acute cholecystitis, necrotizing pancreatitis||CIP, CAZ, IMP, TZP, LIN||May 10||Jul 20||Death||Aug 21|
|2||M/38||Alcoholism||Lung abscess||CIP, CAZ, LIN||Jul 14||Aug 21||Recovery||Oct 20|
|3||M/52||COPD, melitensus diabetes||Necrotizing pneumonia||TZP, CLI, IMP, LIN||Aug 21||Sep 25||Recovery||Oct 30|
|4||M/65||No relevant history||Septic shock||IMP, CIP, TZP, LIN||Sep 17||Oct 28||Recovery||Dec 10|
*CIP, ciprofloxacin; CAZ, ceftazidime; IMP, imipenem; TZP, piperacillin-tazobactam; LIN, linezolid; CLI, clindamycin; COPD, chronic obstructive pulmonary disease.
Page created: December 06, 2010
Page updated: December 06, 2010
Page reviewed: December 06, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.